

External Quality Assessment Program for

Immunosuppressants

Labquality EQAS by Aurevia is introducing a new EQA scheme for immunosuppressive drugs including ciclosporin, tacrolimus, sirolimus and everolimus, by arranging a pilot study free of charge for a limited number of participants. The scheme is suitable for different assays. The EQA samples should be analysed as regular patient samples. Participants submit their results through the electronic platform LabScala, and results are processed by the EQA Coordinator. Results will be evaluated according to method groups based on chemical principles and result levels. Participation is free of charge.

Please note that you can participate in this pilot study for all analytes or only for some of them.

2756 Immunosuppressants

Samples: Lyophilized EDTA whole blood samples

Distribution: March 2025

Registration: Please register by [this link](#) or by scanning this QR code
no later than 17 February 2025



For more information

Aurevia's customer service info@aurevia.com or

Hanna Heikkilä
EQA Coordinator
hanna.heikkila@aurevia.com
+358 50 406 1280

Heidi Berghäll
EQA Solutions manager, R&D
heidi.berghall@aurevia.com
+358 50 356 0503